Latest Share Chat

SUMM.L Share News (SUMM)

SUMM.L Information

There is currently no data for SUMM

Thursday broker round-up UPDATE

Thu, 22nd Aug 2013 07:25

Aggreko: RBC Capital reduces target price from 1850p to 1680p, while its neutral rating remains unchanged.Aviva: JP Morgan raises target price from 393p to 436p and retains an overweight rating.BHP Billiton: Canaccord Genuity takes target price from 1950p to 2050p maintaining a hold recommendation.Cairn Energy: RBC Capital moves target price from 440p to 450p and reiterates its outperform rating.Cropper (James): Westhouse Securities ups target price from 300p to 350p, while downgrading to add.Faroe Petroleum: Liberum Capital lowers target price from 188p to 183p, while leaving its buy recommendation unchanged.Ferrexpo: Cantor Fitzgerald reduces target price from 373p to 290p, but stays with its buy recommendation.Glencore Xstrata: JP Morgan cuts target price from 410p to 390p retaining its overweight rating.Hikma Pharmaceuticals: Jefferies ups target price from 1200p to 1250p and keeps a buy recommendation.Hochschild Mining: Westhouse Securities increases target price from 150p to 200p and reiterates a neutral rating. JP Morgan moves target price from 75p to 80p, while keeping an underweight rating. Citi shifts target price from 133p to 132p and maintains its sell recommendation. RBC Capital ups target price from 220p to 260p and stays with its neutral rating.IMI: Investec places both its target price (prev.: 1350p) and its hold recommendation under review.Intertek Group: Credit Suisse reduces target price from 3850p to 3600p, while retaining an outperform rating.IP Group: Numis lowers target price from 129p to 124p, while its hold recommendation remains unchanged.John Wood Group: JP Morgan cuts target price from 963p to 951p and stays with its neutral rating. Liberum Capital reduces target price from 892p to 874p.Legal & General Group: Morgan Stanley moves target price from 184p to 192p and maintains an equal-weight rating.Lloyds Banking Group: Jefferies shifts target price from 65p to 69p reiterating a hold recommendation.Sportech: Investec lowers target price from 110p to 105p and leaves its buy recommendation unaltered.Stagecoach Group: Deutsche Bank raises target price from 330p to 350p staying with its buy recommendation.Summit Corporation: N+1 Singer shifts target price from 8.80p to 10.70p keeping its buy recommendation.Vitec Group: Investec increases target price from 740 to 810p and retains a buy recommendation.Wolseley: UBS upgrades from neutral to buy with a target price of 3500p.

More News

27 Mar 2019 15:56

Summit Therapeutics Swings To Annual Profit On Sarepta Agreement

LONDON (Alliance News) - Summit Therapeutics PLC on Wednesday said it swung to a profit in its most recent financial year due to the recognition of revenue from its Sarepta Therapeutics Inc pretax

2 Jan 2019 14:08

Polar Capital Holds 6% Summit Therapeutics Stake After Deal (ALLISS)

LONDON (Alliance News) - Summit Therapeutics PLC said Wednesday that Polar Capital LLP holds a 6.47% stake in the drug developer after a transaction on December 21.Polar Capital's the

17 Dec 2018 09:14

Summit Therapeutics proposes $25m fundraiser

(Sharecast News) - Antibiotics developer Summit Therapeutics has entered into a securities purchase agreement for the sale of $25m worth of its US-listed shares in order to extend its cash runway through to January 2020.

11 Dec 2018 16:34

Summit Therapeutics' loss expands on one-off charges

(Sharecast News) - Summit Therapeutics on Tuesday reported that its third quarter loss expanded due to one-off charges, but stated that the company has swung to a profit over the first nine months of the year.

11 Dec 2018 14:31

Summit Therapeutics Third-Quarter Loss Widens Due To One-Off Charges

LONDON (Alliance News) - Summit Therapeutics PLC said Tuesday its third-quarter loss widened sharply due to one-off charges.For the three months ended October 31, the company reported loss

6 Sep 2018 13:55

Summit Therapeutics Discovers New Antibiotics For Superbug Infections

LONDON (Alliance News) - Clinical stage drug company Summit Therapeutics PLC on Thursday said it has discovered multiple new mechanism antibiotics to treat "superbug" antibiotics are at

16 Aug 2018 13:53

Summit Therapeutics Shares Jump As Secures Extra USD12 Million Funding

LONDON (Alliance News) - Summit Therapeutics PLC on Thursday said it secured additional USD12 million from Biomedical Advanced Research & Development Authority, a division of the US Department

20 Apr 2018 13:11

Summit Therapeutics Gets Encouraging Results From Ezutromid Trials

LONDON (Alliance News) - Summit Therapeutics PLC on Friday said new work showed a correlation between a reduction in a muscle damage biomarker and the use of its proposed treatment said analysis a

19 Apr 2018 15:07

Summit Therapeutics Completes Dosing For PhaseOut Clinical Trial

LONDON (Alliance News) - Summit Therapeutics PLC said on Thursday it has completed the ezutromid dosing of patients with Duchenne muscular dystrophy for the full 48-week PhaseOut DMD clinical was

4 Apr 2018 12:53

Tiziana Appoints Leopoldo Zambeletti As Non-Executive Director

LONDON (Alliance News) - Tiziana Life Sciences PLC, a biotechnology company developing drugs for cancer and autoimmune diseases, said Wednesday Leopoldo Zambeletti has joined

27 Mar 2018 12:18

Summit Therapeutics To Raise GBP15 Million Via Share Placing (ALLISS)

LONDON (Alliance News) - Summit Therapeutics PLC said Tuesday that it intends to raise gross proceeds of up to GBP15.0 million via share placing.The to a

14 Mar 2018 17:52

Summit Therapeutics Reports Progress On PhaseOut DMD Trial

LONDON (Alliance News) - Summit Therapeutics PLC at the clinical conference in Arlington highlighted the rigour in the data collection in analysis for its PhaseOut Duchenne 2

1 Feb 2017 16:50

Summit Therapeutics outlines next stage of ridinilazole development

(ShareCast News) - Drug discovery and development company Summit Therapeutics outlined its Phase 3 programme for its novel antibiotic, ridinilazole, following recent regulatory meetings with the US Food and Drug Administration and European Medicines Agency. The AIM-traded firm said, with input from

1 Feb 2017 12:15

Summit Therapeutics Details Phase III Programme For Ridinilazole

18 Jan 2017 12:09

Latest Share Chat

SUMM.L Share News (SUMM)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Thursday broker round-up UPDATE

Login to your account

Quickpicks are a member only feature

Login to your account